Monday, October 02, 2006

Bayer - Trasylol: silence isn't golden

From the WSJ:

US health authorities say the German pharmaceutical giant Bayer kept silent about its own study showing the risks of a drug widely used to avoid complications in heart surgery.

The FDA said Bayer had conducted a study of its drug Trasylol and found it "may increase the chance for death, serious kidney damage, congestive heart failure and strokes."

But Bayer executives said nothing about this study during a meeting with FDA officials on September 21, the US agency said in a statement issued Friday.

More.

Insider's view: Busted!

No comments: